Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study of GS3-007a Dry Suspensions in Healthy Chinese Adults: Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalation, and Food Effect Study
Conditions
Interventions
GS3-007a for Suspension
Placebo GS3-007a for Suspension
Locations
1
China
Yuehong Plaza, No. 88 Hongcao Road, Xuhui District, Shanghai
Shanghai, Shanghai Municipality, China
Start Date
January 7, 2026
Primary Completion Date
June 1, 2026
Completion Date
August 1, 2026
Last Updated
March 16, 2026
NCT07227259
NCT06815991
NCT07305753
NCT07291336
NCT06011018
NCT07130825
Lead Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions